US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

7.33

-0.0800-1.08%

Post-market: 7.32-0.0100-0.14%16:17 EDT

Volume:420.36K

Turnover:3.05M

Market Cap:395.70M

PE:-1.23

High:7.55

Open:7.55

Low:7.07

Close:7.41

52wk High:17.40

52wk Low:7.07

Shares:53.98M

Float Shares:17.65M

Volume Ratio:0.89

T/O Rate:2.38%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.9500

EPS(LYR):-115.2900

ROE:-125.02%

ROA:-36.19%

PB:0.85

PE(LYR):-0.06

Loading ...

Overview Company News Filings

Eikon to present six abstracts at ASCO annual meeting

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics price target lowered to $5 from $7 at Wedbush

Eikon Therapeutics Is Maintained at Underperform by Wedbush

Analyst Reiterates Buy on Eikon Therapeutics, Maintaining $29 December 2026 Price Target on Emerging Oncology Pipeline

Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating

MT Newswires Live

Eikon Therapeutics Highlights Q1 2026 Results and Pipeline

Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate

Benzinga Earnings

Eikon Therapeutics Q1 net loss widens to $83 million

Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics Price Target Maintained With a $7.00/Share by Wedbush

J.P. Morgan Sticks to Their Buy Rating for Eikon Therapeutics, Inc. (EIKN)

Eikon FY25 net loss widens 37% to $333.6 million

Press Release: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/EIKN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":7.33,"timestamp":1790971200000,"preClose":7.41,"halted":0,"volume":420364,"hourTrading":{"tag":"盘后","latestPrice":7.32,"preClose":7.33,"latestTime":"16:17 EDT","volume":5195,"amount":38079.32922,"timestamp":1790972262723,"change":-0.01,"changeRate":-0.001364,"amplitude":0.001364},"delay":0,"changeRate":-0.010796221322537122,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"Post-Mkt","change":-0.08,"latestTime":"10-02 19:15:42 EDT","open":7.55,"high":7.55,"low":7.07,"amount":3054550,"amplitude":0.064777,"askPrice":8.61,"askSize":100,"bidPrice":7.01,"bidSize":13,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790985600000},"marketStatusCode":4,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":7.41,"postHourTrading":{"tag":"盘后","latestPrice":7.32,"preClose":7.33,"latestTime":"16:17 EDT","volume":5195,"amount":38079.32922,"timestamp":1790972262723,"change":-0.01,"changeRate":-0.001364,"amplitude":0.001364},"volumeRatio":0.891602},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.891602,"shares":53984300,"dividePrice":0,"high":7.55,"amplitude":0.064777,"preClose":7.41,"low":7.07,"week52Low":7.07,"pbRate":"0.85","week52High":17.4,"institutionHeld":0,"latestPrice":7.33,"committee":-0.769912,"eps":-5.95,"divideRate":0,"volume":420364,"delay":0,"ttmEps":-5.95,"open":7.55,"prevYearClose":18,"prevWeekClose":7.92,"prevMonthClose":8.04,"prevQuarterClose":8.04,"fiveDayClose":7.92,"twentyDayClose":10.96,"sixtyDayClose":11.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-10-01","current":-1.231933,"percent":0.97546,"low":-3.139466,"twenty":-2.05042,"median":-1.715581,"eighty":-1.520208,"high":-1.329911,"avg":-1.823313,"sd":0.378774,"marketCap":435486841},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072},{"date":"2026-08-28","current":-1.936861,"twenty":-2.105086,"median":-1.736786,"eighty":-1.536491,"marketCap":623981145},{"date":"2026-09-04","current":-1.842708,"twenty":-2.084325,"median":-1.759483,"eighty":-1.536491,"marketCap":593648728},{"date":"2026-09-11","current":-1.54848,"twenty":-2.084271,"median":-1.760899,"eighty":-1.536491,"marketCap":498859926},{"date":"2026-09-18","current":-1.445921,"twenty":-2.066118,"median":-1.742525,"eighty":-1.536172,"marketCap":465819258},{"date":"2026-09-25","current":-1.3938,"twenty":-2.056001,"median":-1.727355,"eighty":-1.530248,"marketCap":449028098},{"date":"2026-10-01","current":-1.351768,"twenty":-2.05042,"median":-1.715581,"eighty":-1.520208,"marketCap":435486841}],"updateTime":1790982942329},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637357662","title":"Eikon to present six abstracts at ASCO annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357662?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:12","pubTimestamp":1779397923,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics will present six oncology abstracts at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago starting May 29, 2026.Data presentations will cover EIK1001 in first-line stage 4 non-small cell lung cancer, including combination regimens with pembrolizumab.Additional updates will include EIK1003 results in advanced solid tumors, including combination work with paclitaxel, alongside early clinical progress for WRN inhibitor candidate EIK1005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL1lZ1YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357327","title":"Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357327","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357327?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:05","pubTimestamp":1779397500,"startTime":"0","endTime":"0","summary":"Presentations to cover progress across Eikon’s most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299796/0/en/Eikon-Therapeutics-Announces-Availability-of-Six-Abstracts-for-Presentation-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4117","AFG","BK4139","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246421","title":"Eikon Therapeutics price target lowered to $5 from $7 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246421","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246421?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:33","pubTimestamp":1778603632,"startTime":"0","endTime":"0","summary":"Wedbush lowered the firm’s price target on Eikon Therapeutics (EIKN) to $5 from $7 and keeps an Underperform rating on the shares after the company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-5-from-7-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-5-from-7-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634117362","title":"Eikon Therapeutics Is Maintained at Underperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2634117362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634117362?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:48","pubTimestamp":1778590080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 08:48 ET (12:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634221925","title":"Analyst Reiterates Buy on Eikon Therapeutics, Maintaining $29 December 2026 Price Target on Emerging Oncology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2634221925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634221925?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:15","pubTimestamp":1778588148,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Eikon Therapeutics, Inc., with a price target of $29.00. Br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-eikon-therapeutics-maintaining-29-december-2026-price-target-on-emerging-oncology-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-eikon-therapeutics-maintaining-29-december-2026-price-target-on-emerging-oncology-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634660219","title":"Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2634660219","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634660219?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:11","pubTimestamp":1778587905,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) has an average rating of overweight and mean price target of $25.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253519","title":"Eikon Therapeutics Highlights Q1 2026 Results and Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253519","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253519?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:06","pubTimestamp":1778533583,"startTime":"0","endTime":"0","summary":"An announcement from Eikon Therapeutics, Inc. ( ($EIKN) ) is now available. Eikon Therapeutics reported its first quarter 2026 results on May 11, 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q1-2026-results-and-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q1-2026-results-and-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237439","title":"Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237439","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237439?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:19","pubTimestamp":1778530780,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analyst consensus estimate of $(4.07) by 39.56 percent. This is a 90.86 percent increase over losses of $(26.91) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52469251/eikon-therapeutics-q1-eps-2-46-beats-4-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634023717","title":"Eikon Therapeutics Q1 net loss widens to $83 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634023717","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634023717?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:17","pubTimestamp":1778530671,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics reported a net loss attributable to common stockholders that widened to USD 83 million, while R&D expense climbed 24% to USD 70 million.G&A expense rose 17% to USD 17.3 million; cash, cash equivalents, and marketable securities totaled USD 596 million as of March 31, 2026.R&D increase reflected accelerating clinical trial activity and a USD 5 million milestone payment to Impact Therapeutics tied to advancing EIK1003 into Phase 2 development.Eikon forecast current cash resources to fund operations into the second half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLhWGMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232507","title":"Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232507","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232507?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:02","pubTimestamp":1778529720,"startTime":"0","endTime":"0","summary":"-- Maintained strong financial position with $596 million in cash, cash. equivalents and marketable securities as of March 31, 2026. -- Continued execution across the oncology pipeline, with a strategic focus. on three priority programs: EIK1001, a Toll-like receptor 7/8 . agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor,-- Six abstracts accepted for the American Society of Clinical Oncology.  annual meeting highlighting new data from the company's lead. programs including new safety, tolerability, and efficacy data. discovery programs in the absence of robust biochemical assays. \"We made meaningful progress in the first quarter advancing our oncology programs and expanding the clinical evidence supporting their potential, \" said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics. \"We are particularly encouraged by the breadth of data emerging across our pipeline, which will be featured at the ASCO annual meeting, and we","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","BK4585","BK4588","LU0210528500.USD","BK4107","EIKN","BK4139","L","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580208","title":"Eikon Therapeutics Price Target Maintained With a $7.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623580208?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:27","pubTimestamp":1774967220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 10:27 ET (14:27 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623158770","title":"J.P. Morgan Sticks to Their Buy Rating for Eikon Therapeutics, Inc. (EIKN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623158770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623158770?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:56","pubTimestamp":1774965401,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Cheng from J.P. Morgan reiterated a Buy rating on Eikon Therapeutics, Inc., with a price target of $29.00. Ch...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-eikon-therapeutics-inc-eikn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-eikon-therapeutics-inc-eikn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623138312","title":"Eikon FY25 net loss widens 37% to $333.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623138312","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623138312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:55","pubTimestamp":1774871710,"startTime":"0","endTime":"0","summary":"Eikon posted a full-year net loss attributable to common stockholders of $334 million, widening from $244 million.Operating loss expanded to $339 million as research and development expense climbed 22% to $250 million.General and administrative costs jumped 59% to $89 million, driven mainly by a $21 million impairment tied to vacated properties.Cash, cash equivalents, and marketable securities totaled $336 million at year-end; an upsized IPO in February raised $381 million in gross proceeds.Completed enrollment in TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 non-small cell lung cancer, with a comprehensive data set expected in 2H 2026; cash runway forecast into 2H 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eiko","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL95SGYj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312506","title":"Press Release: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312506","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312506?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:48","pubTimestamp":1774871280,"startTime":"0","endTime":"0","summary":"-- Closed upsized initial public offering in February 2026, raising $381. -- Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in. first-line treatment of stage 4 non-small cell lung cancer. MILLBRAE, Calif., March 30, 2026  -- Eikon Therapeutics, Inc.  , a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates.\"2025 was an important year of progress for Eikon's business and clinical programs,\" said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. \"With our initial public offering, and the consequent strengthening of our balance sheet, we believe we are well-positioned to advance multiple registration-enabling programs, bringing us closer to our mission of delivering breakthrough therapeutics to patients with serious illnesses.\". EIK1001 is a systemically administ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","L","LU0053666078.USD","LU0210528500.USD","BK4585","BK4588","EIKN","LU2487616109.SGD","BK4107"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}]}}